BioXcel Therapeutics (BTAI) FCF Margin (2022 - 2026)
BioXcel Therapeutics' (BTAI) quarterly FCF Margin came in at 5732.52% in Q1 2026, up 143593.0% year-on-year from N/an in Q1 2025, and down 3.27% quarter-over-quarter from 5550.78% in Q4 2025.
BioXcel Therapeutics (BTAI) FCF Margin (2022 - 2026) Analysis & Trends
BioXcel Therapeutics' FCF Margin history runs 5 years deep, the most recent figure standing at 5732.52% for Q1 2026.
- On a quarterly basis, FCF Margin rose 143593.0% year-over-year to 5732.52% in Q1 2026; TTM through Mar 2026 was 8438.38%, a 485501.0% decrease from a year earlier, with the FY2025 full-year figure at 8974.3%, down 579570.0% from the prior year.
- FCF Margin fell to 5732.52% in Q1 2026 per BTAI's latest filing, from 5550.78% in the prior quarter.
- Across five years, FCF Margin topped out at 2099.09% in Q2 2024 and bottomed at 25414.08% in Q1 2023.
- The 5-year median for FCF Margin is 7634.58% (2024), against an average of 10390.81%.
- Across the five-year window, FCF Margin jumped 2237181 bps in 2024 and plunged 1153583 bps in 2025, its largest moves.
- Year by year, FCF Margin stood at 16234.87% in 2022, then jumped by 56 bps to 7144.41% in 2023, then jumped by 43 bps to 4046.17% in 2024, then plunged by 37 bps to 5550.78% in 2025, then fell by 3 bps to 5732.52% in 2026.
- Per Business Quant, the three latest BTAI FCF Margin figures stand at 5732.52% (Q1 2026), 5550.78% (Q4 2025), and 19170.41% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -5.22% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 12.86% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -5.35% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 46.54% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 9.93% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 17.73% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -2.77% |
| 10 | BioXcel Therapeutics | 10.62 Mn | 10.62 Mn | -77,000.00 | -5,732.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5,732.52% |
| Dec 31, 2025 | -5,550.78% |
| Sep 30, 2025 | -19,170.41% |
| Jun 30, 2025 | -10,479.17% |
| Mar 31, 2025 | -7,168.45% |
| Dec 31, 2024 | -4,046.17% |
| Sep 30, 2024 | -7,634.58% |
| Jun 30, 2024 | -2,099.09% |
| Mar 31, 2024 | -3,042.27% |
| Dec 31, 2023 | -7,144.41% |
| Sep 30, 2023 | -11,021.70% |
| Jun 30, 2023 | -8,360.18% |
| Mar 31, 2023 | -25,414.08% |
| Dec 31, 2022 | -16,234.87% |
| Sep 30, 2022 | -22,763.50% |